

5000

PST
#3

PATENT APPLICATION


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Hans Berg ANDREASEN, et

Appln. No. 09/509,681

Filed: March 30, 2000



529 Rec'd PCT/PTO 19 JUN 2000

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

For: A PROCESS FOR PRODUCING AN IRON-DEXTRAN COMPOUND,
IRON-DEXTRAN COMPOUND PRODUCED ACCORDING TO SAID PROCESS,
PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF
IRON-DEFICIENCY AND USE OF SAID COMPOUND FOR THE

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 and/or listed herein and which the Examiner may deem relevant to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith.

The present Information Disclosure Statement is being filed (1) no later than three months from the application's filing date or (2) before the mailing date of the first Office Action on the merits (whichever is later), and therefore no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No. 09/509,681

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant submits the following explanations:

DK 117,730 (1970) describes a process in which hydrogenated dextran having a molecular weight between 2,000 and 10,000 Daltons is reacted with ferric hydroxide in aqueous medium to form an iron dextran complex. The average molecular weight of the dextran used in the embodiment examples is not indicated. However, the intrinsic viscosity is stated as approximately 0,05 which could correspond to an average molecular weight of approximately 5,000 Daltons.

DK 122,398 (1972) discloses the use of hydrogenated dextran for preparing complex compounds with ferric hydroxide, and it is explained that a substantial lower toxicity is obtained than when non-hydrogenated dextran is used. The subject of the patent is a process in which moist ferric hydroxide is mixed with dry hydrogenated dextran, and after optional addition of citric acid or citrate the mixture is heated and purified.


DK 129,353 (1974) is directed on an analogy process for producing a ferric hydroxide-dextran derivative at an average molecular weight of the dextran of at the most 50,000 Daltons, and the terminal groups of the polymer chains thereof have been modified to convert the terminal reducing anhydroglucose unit into a corresponding carboxylic acid group. The limits indicated for molecular weight of the dextran are from 500 to 50,000 Daltons, preferably from 1,000 to 10,000 Daltons. The only exemplified dextran has an average molecular weight of 5, 000 Daltons.

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No. 09/509,681

DK 129,942 (1974) and describes the manufacture of ferric hydroxide complexes with dextran hepton acid or dextrine hepton acid. The hepton acids are prepared by hydrolysing the corresponding dextran cyanhydrids.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Brian W. Hannon", written over a horizontal line.

Brian W. Hannon
Registration No. 32,778

SUGHRUE, MION, ZINN,
MACPEAK & SEAS, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3213
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Date: June 19, 2000